問卷

TPIDB > Search Result

Search Result

篩選

List

20Cases

2025-09-01 - 2028-09-01

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-12-23 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2025-09-22 - 2029-03-18

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-01-22 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2024-11-15 - 2027-02-16

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-27 - 2028-05-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-04-01 - 2026-08-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-09-30 - 2026-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-07-07 - 2025-12-31

Phase I

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab
  • Condition/Disease

    Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma

  • Test Drug

    ABBV-514ABBV-181 (Budigalimab)

Participate Sites
5Sites

Recruiting5Sites

1 2